Hierarchical local binary pattern for branch retinal vein occlusion recognition with fluorescein angiography images

2014 ◽  
Vol 50 (25) ◽  
pp. 1902-1904 ◽  
Author(s):  
Hui Zhang ◽  
Zenghai Chen ◽  
Zheru Chi ◽  
Hong Fu

Even though the diagnosis depends on clinical examination, in cases with branch retinal vein occlusion (BRVO), fundus fluorescein angiography (FFA), optical coherence tomography (OCT), and optical coherence tomography angiography (OCTA) provide unique data for follow-up, management and prognosis. In FFA, delay of laminar flow phase in the involved branch, hyperfluorescence due to leakage from the vessel wall in the late phases, hypofluorescence due to the blockage by hemorrhage, and soft exudates, and hyperfluorescence due to macular edema can be detected. In OCT, macular thickening, cystic spaces, serous retinal detachment, hyperreflective dots, disorganization of the outer retinal layers – particularly the photoreceptor inner and outer segments line and the external limiting membrane – can be seen. OCTA reveals non-perfusion, particularly in the deep capillary plexus.


2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Hisanori Imai ◽  
Akira Tetsumoto ◽  
Hiroko Yamada ◽  
Mayuka Hayashida ◽  
Keiko Otsuka ◽  
...  

2000 ◽  
Vol 10 (2) ◽  
pp. 177-179 ◽  
Author(s):  
C. Peris Martínez ◽  
J.A. Aviñó Martínez ◽  
M. Díaz-Llopis ◽  
E. España Gregori ◽  
J.L. Menezo ◽  
...  

Purpose To describe a case of branch retinal vein occlusion (BRVO) in a patient who tested positive for the 20210 A allele of the prothrombin (PT) gene. Methods A 48-year-old man had visual loss in the right eye secondary to BRVO confirmed by ophthalmoscopy and fluorescein angiography. His medical history was not remarkable for common risk factors for retinal occlusive diseases. Results Laboratory tests for hypercoagulability were positive for PT 20210 A variant. The patient's family tested negative for the PT variant. Conclusions Laboratory tests for coagulopathy, including the PT 20210 A variant, should be added to the examination of patients with central or BRVO, especially if most common risk factors for thrombosis have been excluded.


Branch retinal vein occlusion (BRVO) is classified according to the anatomical location as a major, hemiretinal, or macular. BRVO is further classified into perfused (non-ischemic) or nonperfused (ischemic). Ischemic BRVO is defined as more than 5 disc diameters of nonperfusion on fluorescein angiography (FA). There is a significant contribution of FA and Optical Coherence Tomography in predicting treatment and determining prognosis.


2018 ◽  
Vol 61 (2) ◽  
pp. 107-114 ◽  
Author(s):  
Yusuke Yasuda ◽  
Yoshio Hirano ◽  
Yuya Esaki ◽  
Taneto Tomiyasu ◽  
Norihiro Suzuki ◽  
...  

2018 ◽  
Vol 9 (1) ◽  
pp. 248-253 ◽  
Author(s):  
Kajo Bucan ◽  
Ivna Plestina Borjan ◽  
Ivona Bucan ◽  
Martina Paradzik Simunovic ◽  
Ivan Borjan

The authors report a rare case of nonischemic branch retinal vein occlusion and nonischemic hemiretinal vein occlusion in a patient with impaired fibrinolysis. A 61-year-old woman presented to the Department of Ophthalmology, Clinical Hospital Center Split, Croatia, with acute blurring of vision in the right eye (RE) due to branch retinal vein occlusion. Ophthalmologic evaluation revealed a best corrected visual acuity (BCVA) of 0.02 in the RE and of 1.0 in the left eye. Ophthalmoscopy and fluorescein angiography of the RE demonstrated signs of nonischemic branch retinal vein occlusion. She was otherwise healthy and had no other ocular and systemic diseases. She was treated with 3 consecutive intravitreal applications of anti-vascular endothelial growth factor (anti-VEGF; bevacizumab) due to cystoid macular edema with full resolution of the intraretinal fluid and improvement of the BCVA to 0.9. After 8 months, she presented again with acute blurring of vision in the same (right) eye with a BCVA of 0.5. Ophthalmoscopy and fluorescein angiography of the RE indicated nonischemic hemiretinal vein occlusion. She was treated with a single intravitreal application of anti-VEGF (ranibizumab) due to macular edema. Full resolution of the intraretinal fluid and improvement of the BCVA to 0.9 were achieved. A laboratory workup was performed to rule out all known causes of retinal venous occlusive disease, which showed negative results. A molecular analysis showed the gen of thrombophilia – plasminogen activator inhibitor (PAI)-1 4G/5G polymorphism genotype – as the only risk factor for retinal venous occlusive disease in our patient.


Sign in / Sign up

Export Citation Format

Share Document